Total revenue for the third quarter was $302.3 million, an increase of $73.2 million or 32.0% over the prior year quarter; Net income for the third quarter was $9.6 million, an increase of $3.6 ...
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically suppressed people living with HIV-1, along with an encore ...
First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profile; VECTRA trial will ...
Enrollment began in the U.S. in June 2022 and expanded to China, New Zealand, Australia, and India. The topline results summary reports 659 patients: 164 assigned to CBT-001 0.1%, 329 to CBT-001 0.2%, ...
In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm AIHA (“wAIHA”) are currently under regulatory review by the National Medical Products Administration (NMPA), supported ...
Group adj. EBITA (continuing operations) ended at DKK 413 million, equal to an adj. EBITA margin of 18.2%, compared to 8.8% in Q3 2025 reflecting tariff refunds of DKK 153 million, as well as a ...
Agreement reinforces Boehringer Ingelheim’s long-term commitment to China’s innovation ecosystem and validates SBP Group’s innovative R&D capabilities Ingelheim, Germany, and Hong Kong/China, 4 ...
NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease.
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 ...
Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will ...
GAAP net loss per share for the third quarter of 2026 was $0.12 compared to $0.13 for the third quarter of 2025. Non-GAAP net loss per share for the third quarter of 2026 was $0.11 compared to $0.12 ...
Net Product Revenue: RASONQUE net product revenue was $197.6 million for the quarter ended September 30, 2026, reflecting approximately five weeks of commercial availability following U.S. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results